Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

Running, not enrolling

Conditions studied: Pancreatic Cancer

In brief

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

Key facts

Study ID

NCT01580241

Run by

University of Oklahoma

People needed

60

Starts

2010-10-01

Expected to finish

2027-12-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• pancreatic cancer

You may not qualify if…

• age < 18, history of other types of cancer

Where it is running

• Stephensen Cancer Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.